The introduction of immune checkpoint inhibitors has resulted in a paradigm shift in the management of advanced medlinklung cancer/medlink, resulting in longer patient lives and improved overall survival.
However, one critical question remains unanswered: What is the appropriate duration of immunotherapy for patients with advanced non-small cell lung cancer (NSCLC) who receive it as their first treatment? (!--ref1--).
According to a new retrospective cohort study published in JAMA Oncology ...
The introduction of immune checkpoint inhibitors has resulted in a paradigm shift in the management of advanced medlinklung cancer/medlink, resulting in longer patient lives and improved overall survival.
However, one critical question remains unanswered: What is the appropriate duration of immunotherapy for patients with advanced non-small cell lung cancer (NSCLC) who receive it as their first treatment? (!--ref1--).
According to a new retrospective cohort study published in JAMA Oncology ...